Hannah Findlay

hero

About

RoukenBio - Hannah Findlay.png
MSc Medical Genetics and Genomics
University of Glasgow
Flow cytometry, Assay development, PCR
Senior Innovation Scientist

Hannah is a Senior Scientist in our Innovation team. After completing an MSc in Genetics and Genomics, Hannah worked in process development in cancer cell therapy research before joining RoukenBio in 2020. 

Resources

202608 - Development of a high-throughput multimodal patient-derived platform integrating autologous fibroblasts and tumour-infiltrating lymphocytes for colorectal cancer drug discovery .png

https://website-content.rouken.bio/research_poster_039a1b785f.svgResearch Posters

|

17 August 2026

|

4 min read

Development of a high-throughput multimodal patient-derived platform integrating autologous fibroblasts and tumourinfiltrating lymphocytes for colorectal cancer drug discovery

This research poster presents a high-throughput, patient-derived colorectal cancer tumoroid platform incorporating autologous fibroblasts and tumour-infiltrating lymphocytes. By combining genomic, gene-expression and drug-response data, the model captures patient-specific tumour heterogeneity and supports translational drug discovery, predictive biomarker identification and immunotherapy research.

Antigen Specific T Cells for Assessing Immune Modulating Therapeutics.png

https://website-content.rouken.bio/research_poster_039a1b785f.svgResearch Posters

|

22 October 2025

|

4 min read

Antigen Specific T Cells for Assessing Immune Modulating Therapeutics

Antigen-specific T cells are essential for evaluating immune-modulating therapies, but sourcing them for research is challenging. This blog highlights the development of ‘Thaw & Go’ transgenic TCR-T cell banks and methods to expand endogenous antigen-specific T cells, providing ready-to-use resources for high-throughput assessment of immune modulators and advancing drug discovery efforts.

202507 - Target density Matters.png

https://website-content.rouken.bio/research_poster_039a1b785f.svgResearch Posters

|

16 July 2025

|

5 min read

Target density matters: Binding kinetics of antibody-based therapeutics are highly influenced by target expression levels

Understanding how antibody-based drugs interact with targets at different expression levels is key to optimising their safety and efficacy. Traditional methods struggle to measure binding kinetics in real cellular environments. This study uses the IndEx-2 system and single-cell Interaction Cytometry to reveal how target density affects drug binding in a more physiologically relevant context.